A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Last updated: May 16, 2014
Sponsor: Pfizer
Overall Status: Terminated

Phase

1

Condition

Memory Loss

Dementia

Alzheimer's Disease

Treatment

N/A

Clinical Study ID

NCT01028911
A8801016
  • Ages 55-85
  • All Genders

Study Summary

This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Probable Alzheimer's disease

  • Mini Mental State Examination score 18-26 inclusive

  • Aged 55-85

Exclusion

Exclusion Criteria:

  • Dementia other than Alzheimer's disease

  • Clinically significant cardiovascular disease in the past 6 months prior to screening

  • Creatinine clearance <30 mL/min

Study Design

Total Participants: 9
Study Start date:
December 01, 2009
Estimated Completion Date:
May 31, 2010

Connect with a study center

  • Pfizer Investigational Site

    Wichita, Kansas 67207
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.